Skip to main content
SpringerLink
Log in

Immuntherapie des Lungenkarzinoms

Zwischen Hoffnung und Hype

Immunotherapy of lung cancer

Between hope and hype

  • Leitthema
  • Published:
Der Pneumologe Aims and scope

Zusammenfassung

Die Immuntherapie in Form der Checkpoint-Inhibition erweist sich beim nicht-kleinzelligen Lungenkarzinom (NSCLC) als wirksam. Insbesondere Inhibitoren des PD-1-Rezeptors (programmed cell death 1) oder seines Liganden PD-L1 sind der konventionellen Chemotherapie in vielen Therapiesituationen überlegen. Die Rolle der Inhibition von CTLA-4 (cytotoxic T‑lymphocyte-associated antigen 4) und von Kombinationstherapien sind Gegenstand der klinischen Forschung. Längeres Überleben, bessere Verträglichkeit und längere Remissionen sind die Vorteile, ein deutlich höherer Preis und das Fehlen eines validen Selektionsbiomarkers die Nachteile dieser neuen Therapieform.

Abstract

Immunotherapy by means of checkpoint inhibition has been proven to be effective in non-small cell lung cancer (NSCLC). Inhibitors of the programmed cell death 1 (PD-1) receptor or its ligand PD-L1 in particular are more effective than conventional chemotherapy in many therapeutic settings. The role of cytotoxic T‑lymphocyte-associated antigen 4 (CTLA-4) inhibitors as well as combination therapies are currently the subject of clinical investigations. Improved survival, better tolerability and long-lasting remission are the advantages but the excess costs and the lack of a valid biomarker are the drawbacks of this new therapeutic option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Attarwala H (2010) TGN1412: from discovery to disaster. J Young Pharm 2:332–336

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus Docetaxel in advanced Nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639

    Article  CAS  PubMed  Google Scholar 

  3. Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135

    Article  CAS  PubMed  Google Scholar 

  4. Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Carbognin L, Pilotto S, Milella M et al (2015) Differential activity of Nivolumab, Pembrolizumab and MPDL3280 A according to the tumor expression of programmed death-Ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS ONE 10:e0130142

    Article  PubMed  PubMed Central  Google Scholar 

  6. Erfani N, Mehrabadi SM, Ghayumi MA et al (2012) Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer 77:306–311

    Article  PubMed  Google Scholar 

  7. Gettinger SN, Horn L, Gandhi L et al (2015) Overall survival and long-term safety of Nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33:2004–2012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Heigener D, Reck M (2015) Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer. Expert Rev Anticancer Ther 15:69–83

    Article  CAS  PubMed  Google Scholar 

  9. Herbst RS, Baas P, Kim DW et al (2015) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550

    Article  PubMed  Google Scholar 

  10. Herbst RS, Soria JC, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280 A in cancer patients. Nature 515:563–567

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Horn L (2015) Phase 3, randomized trial (checkmate 057) of Nivolumab vs Docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient-reported outcomes (PRos ESMO Asia. ESMO, Singapore.

    Google Scholar 

  12. Ko JS, Zea AH, Rini BI et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15:2148–2157

    Article  CAS  PubMed  Google Scholar 

  13. Le DT, Uram JN, Wang H et al (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372:2509–2520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Lynch TJ, Bondarenko I, Luft A et al (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30:2046–2054

    Article  CAS  PubMed  Google Scholar 

  15. Nishimura H, Nose M, Hiai H et al (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141–151

    Article  CAS  PubMed  Google Scholar 

  16. Reck M, Kaiser R, Mellemgaard A et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15:143–155

    Article  CAS  PubMed  Google Scholar 

  17. Reck M, Popat S, Reinmuth N et al (2014) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 25(Suppl 3):iii27–iii39

    Article  PubMed  Google Scholar 

  18. Rizvi N, Gettinger S, Goldman J et al (2015) Safety and efficacy of first-line Nivolumab (NIVO; anti-programmed death-1 [PD-1]) and Ipilimumab in non-small cell lung cancer (NSCLC). In 15th World Conference on Lung Cancer, Denver.

  19. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Vansteenkiste J, Fehrenbacher B, Spira A et al (2015) Atezolizumab monotherapy vs docetaxel in 2 L/3 L non-small cell lung cancer: Primary analyses for effcacy, safety and predicitve biomarkers from a randomised phase II study (POPLAR). In ECCO/ESMO Conference, Vienna.

    Google Scholar 

  21. Voron T, Marcheteau E, Pernot S et al (2014) Control of the immune response by pro-angiogenic factors. Front Oncol 4:70

    Article  PubMed  PubMed Central  Google Scholar 

  22. Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Onkologischer Schwerpunkt, LungenClinic Grosshansdorf, Airway Research Center North (ARCN) im Deutschen Zentrum für Lungenforschung (DZL), Wöhrendamm 80, 22927, Grosshansdorf, Deutschland

    D. F. Heigener, P. Steffen & M. Reck

Authors
  1. D. F. Heigener
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Steffen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Reck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. F. Heigener.

Ethics declarations

Interessenkonflikt

D. F. Heigener ist Mitglied in Advisory Boards bei Roche, Lilly, Boehringer Ingelheim, Bristol Myers-Squibb und Pfizer und hat auch Vortragshonorare von diesen Firmen erhalten. P.S. gibt an, dass kein Interessenkonflikt besteht. M. Reck gibt an, dass Honorare für Beratung (Advisory Boards): Hoffmann-La Roche, Lilly, MSD, BMS, AstraZeneca, Boehringer-Ingelheim, Pfizer, Novartis, Celgene und Honorare für Vorträge: Hoffmann-La Roche, Lilly, MSD, BMS, AstraZeneca, Boehringer-Ingelheim, Pfizer, Celgene erhalten wurden.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

B. Jany, Würzburg

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heigener, D.F., Steffen, P. & Reck, M. Immuntherapie des Lungenkarzinoms. Pneumologe 13, 249–254 (2016). https://doi.org/10.1007/s10405-016-0046-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-016-0046-1

Schlüsselwörter

Keywords

Search

Navigation